医学
新辅助治疗
食管切除术
内科学
食管癌
单变量分析
完全响应
阶段(地层学)
胃肠病学
癌症
队列
模式治疗法
T级
肿瘤科
外科
核医学
多元分析
化疗
乳腺癌
古生物学
生物
作者
Claire L. Donohoe,Naoimh J. O’Farrell,Tim Grant,Sinéad King,Lindsey Clarke,Cian Muldoon,John V. Reynolds
出处
期刊:Annals of Surgery
[Ovid Technologies (Wolters Kluwer)]
日期:2013-11-01
卷期号:258 (5): 784-792
被引量:79
标识
DOI:10.1097/sla.0b013e3182a66588
摘要
In Brief Objective: To assess existing measures of pathologic response to neoadjuvant therapy in esophageal and junctional cancer, and to recommend an optimum classification. Background: Multimodal therapy is increasingly the standard of care for locally advanced esophageal cancer. Numerous measures of pathologic response have been studied; however, no international standardization exists and no measure is incorporated into the current American Joint Committee on Cancer staging system. Methods: A total of 393 consecutive patients completing multimodal therapy were studied, all with prospectively recorded Mandard tumor regression grades (TRG). Seven other published methods of response were compared, and a novel 3-point TRG [TRG 1 (complete); TRG 2/3 (partial); TRG 4/5 (none/minimal)] was tested. Clinical and pathologic evidence of nodal regression was assessed in a consecutive subset of 200 comprehensively staged patients. Results: All models had similar discriminatory and stratification power, and they predicted survival (P < 0.0001) on univariate analysis. Conversely, only the 3-point TRG (P = 0.042) along with ypN (P < 0.001) and ypT stage (P < 0.001) independently predicted survival. The median survival for TRG 1 was 71 months compared with 30 and 17 months for TRG 2/3 and TRG 4/5, respectively (P < 0.0001). Apparent complete nodal response (cN1 to ypN0) was seen in 64% of the TRG 1 group, 30% of the TRG 2/3 group, and 5% of the TRG 4/5 group (P < 0.0001). Conclusions: No existing response measure independently predicts outcome. A complete response (TRG 1) defines a unique cohort after neoadjuvant therapy, associated closely with nodal response, and overall survival. This classification merits consideration for standardization of treatment response, and for inclusion in staging nomenclature. Several measures of pathologic regression to neoadjuvant therapy are reported. Here, in a large consecutive cohort, no published measure independently impacted on survival. A simplified novel 3-point scoring system was significant and discriminated with respect to both nodal response and survival.
科研通智能强力驱动
Strongly Powered by AbleSci AI